Literature DB >> 29304441

Cloning, purification and biochemical characterization of two β-N-acetylhexosaminidases from the mucin-degrading gut bacterium Akkermansia muciniphila.

Meng Wang1, Xiao-Yang Zhang1, Rui-Rui Guo1, Zhi-Peng Cai1, Xiao-Chun Hu1, Huan Chen1, Shuang Wei1, Josef Voglmeir2, Li Liu3.   

Abstract

Two genes encoding the β-N-acetylhexosaminidases Am2301 and Am2446 were cloned successfully from the mucin-degrading bacterium Akkermansia muciniphila. The recombinant enzymes with molecular masses of 61 kDa and 78 kDa were isolated and biochemically characterised. The optimum temperature of both enzymes was 37 °C, and the optimum pH was determined to be pH 5.0 for Am2301 and pH 6.5 for Am2446. The addition of sodium dodecyl sulphate (SDS) reduced the enzymes' activity significantly. Cu2+-ions decreased the activity of Am2301 by 70%, while the activity of Am2446 was significantly reduced by Fe3+-ions. PugNAc strongly inhibited both enzymes already in the sub-micromolar concentration range. The enzymes catalysed the hydrolysis of β1,4-linked N-acetylgalactosamine and β1,6-linked N-acetylglucosamine from glycan standards, as well as β1,2-linked N-acetylglucosamine units from the non-reducing end of N-glycans. The present study describes the first functional characterisation of β-N-acetylhexosaminidases from this human gut symbiont.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Akkermansia muciniphila; Glycan degradation; Intestinal glycosidases; β-N-acetylhexosaminidases

Mesh:

Substances:

Year:  2017        PMID: 29304441     DOI: 10.1016/j.carres.2017.12.007

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  7 in total

1.  Revisiting the role of Akkermansia muciniphila as a therapeutic bacterium.

Authors:  Jiyeon Si; Hyena Kang; Hyun Ju You; GwangPyo Ko
Journal:  Gut Microbes       Date:  2022 Jan-Dec

2.  Cloning, purification and biochemical characterisation of a GH35 beta-1,3/beta-1,6-galactosidase from the mucin-degrading gut bacterium Akkermansia muciniphila.

Authors:  Bi-Shan Guo; Feng Zheng; Lucy Crouch; Zhi-Peng Cai; Meng Wang; David N Bolam; Li Liu; Josef Voglmeir
Journal:  Glycoconj J       Date:  2018-05-12       Impact factor: 2.916

3.  Transcriptomics and metabolomics reveal the adaption of Akkermansia muciniphila to high mucin by regulating energy homeostasis.

Authors:  Xinyue Liu; Fan Zhao; Hui Liu; Yunting Xie; Di Zhao; Chunbao Li
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

4.  A Novel GH Family 20 β-N-acetylhexosaminidase With Both Chitosanase and Chitinase Activity From Aspergillus oryzae.

Authors:  Tianle Qu; Chunyue Zhang; Zhen Qin; Liqiang Fan; Lihua Jiang; Liming Zhao
Journal:  Front Mol Biosci       Date:  2021-05-19

5.  Akkermansia muciniphila uses human milk oligosaccharides to thrive in the early life conditions in vitro.

Authors:  Ioannis Kostopoulos; Janneke Elzinga; Noora Ottman; Jay T Klievink; Bernadet Blijenberg; Steven Aalvink; Sjef Boeren; Marko Mank; Jan Knol; Willem M de Vos; Clara Belzer
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

6.  Study of growth, metabolism, and morphology of Akkermansia muciniphila with an in vitro advanced bionic intestinal reactor.

Authors:  Zhitao Li; Guoao Hu; Li Zhu; Zhenglong Sun; Yun Jiang; Min-Jie Gao; Xiaobei Zhan
Journal:  BMC Microbiol       Date:  2021-02-23       Impact factor: 3.605

7.  Type 1 diabetes in pregnancy is associated with distinct changes in the composition and function of the gut microbiome.

Authors:  Alexandra J Roth-Schulze; Megan A S Penno; Katrina M Ngui; Helena Oakey; Esther Bandala-Sanchez; Alannah D Smith; Theo R Allnutt; Rebecca L Thomson; Peter J Vuillermin; Maria E Craig; William D Rawlinson; Elizabeth A Davis; Mark Harris; Georgia Soldatos; Peter G Colman; John M Wentworth; Aveni Haynes; Simon C Barry; Richard O Sinnott; Grant Morahan; Naiara G Bediaga; Gordon K Smyth; Anthony T Papenfuss; Jennifer J Couper; Leonard C Harrison
Journal:  Microbiome       Date:  2021-08-06       Impact factor: 14.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.